CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a $73M Series B financing round led by ...
Hosted on MSN
A light-and-sound headset for Alzheimer’s is finishing a major late-stage trial this month
Cognito Therapeutics is wrapping up the largest clinical trial ever conducted on a non-drug device for Alzheimer’s disease. The HOPE study, a randomized, double-blind, sham-controlled trial of the ...
Top-tier investor syndicate led by FoundersX Ventures, with participation from all existing investors and new investors Alzheimer’s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results